JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by Fluit, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by Fluit, A. C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2001, p. 3724-3726, Vol. 39, No. 10
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.10.3724-3726.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Increased Prevalence of Class I Integrons in Escherichia coli, Klebsiella Species, and Enterobacter Species Isolates over a 7-Year Period in a German University Hospital

Franz-Josef Schmitz,1,2,* Dieter Hafner,3 Roland Geisel,1 Patrick Follmann,1 Christian Kirschke,1 Jan Verhoef,2 Karl Köhrer,1 and Ad C. Fluit2

Institute for Medical Microbiology and Virology1 and Institute of Pharmacology and Clinical Pharmacology,3 Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, and Eijkman-Winkler Institute for Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands2

Received 28 December 2000/Returned for modification 31 May 2001/Accepted 18 July 2001

The prevalence of integrons in five enterobacterial species was analyzed in 900 blood culture isolates from 1993, 1996, and 1999. Remarkably, the prevalence increased from 4.7% in 1993 to 9.7% in 1996 and finally to 17.4% in 1999 (P < 0.01). Within 7 years the combined percentage of P1 strong promoters and P1 weak plus P2 active promoters with high transcription efficacies has increased from 23.1 to 33.3 and finally 60% (P < 0.05).

* Corresponding author. Mailing address: Institute for Medical Microbiology and Virology, Heinrich-Heine-University Düsseldorf, Universitätsstraße 1, Geb. 22.21, D-40225 Düsseldorf, Germany. Phone and fax: 0049-2132-72040. E-mail: schmitfj{at}uni-duesseldorf.de.

Journal of Clinical Microbiology, October 2001, p. 3724-3726, Vol. 39, No. 10
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.10.3724-3726.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.